Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TRC051384 is a heat shock protein 70 (HSP70) inducer that reduces stroke-associated neuronal damage and increases survival in a rat model of transient ischemic stroke, activates heat shock factor-1 and leads to elevated molecular chaperone and anti-inflammatory activity, and enhances Hsp72 expression in neurons and glial cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 45.00 | |
2 mg | In stock | $ 64.00 | |
5 mg | In stock | $ 101.00 | |
10 mg | In stock | $ 182.00 | |
25 mg | In stock | $ 377.00 | |
50 mg | In stock | $ 552.00 | |
100 mg | In stock | $ 787.00 | |
200 mg | In stock | $ 1,070.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 110.00 |
Description | TRC051384 is a heat shock protein 70 (HSP70) inducer that reduces stroke-associated neuronal damage and increases survival in a rat model of transient ischemic stroke, activates heat shock factor-1 and leads to elevated molecular chaperone and anti-inflammatory activity, and enhances Hsp72 expression in neurons and glial cells. |
In vitro | TRC051384 induces HSP70B mRNA by several hundred folds in both HeLa and rat primary mixed neurons in a dose-dependently manner. Treatment with TRC051384 results in a significant dose-dependent increase in HSF1 transcriptional activity and recovery of luciferase activity. TRC051384 results in 60% inhibition at 6.25 μM and 90% inhibition at 12.5 μM of LPS-induced TNF-α expression in differentiated THP-1 cell line[1]. |
In vivo | Treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even though administered 8 hours post onset of ischemia. Significant improvement in survival (50% by day2 and 67.3% by day 7) is observed with TRC051384 treatment initiated at 4 hours after ischemia onset. Induction of HSP70 by TRC051384 involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity[1]. |
Cell Research | HeLa cell transiently co-transfected with heat shock elements-luciferase reporter and normalization vector, β-galactosidase are treated with vehicle or TRC051384 (12.5 and 25 μM) for 4 hours. Cell lysates are then prepared and analyzed for luciferase and β-galactosidase activity[1]. |
Synonyms | TRC 051384 |
Molecular Weight | 465.54 |
Formula | C25H31N5O4 |
CAS No. | 867164-40-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TRC051384 867164-40-7 Cytoskeletal Signaling Metabolism HSP TRC-051384 TRC 051384 Heat shock proteins Inhibitor inhibit inhibitor